Trump Announces Major Drug Pricing Deal with Regeneron

Trump Announces Major Drug Pricing Deal with Regeneron: A Comprehensive Summary

President Trump unveils a significant drug pricing agreement with Regeneron Pharmaceuticals, concluding a year-long administration push to lower costs for Americans. The deal aligns with Trumps Most Favored Nation initiative, matching U.S. prices with those in other developed nations. Regeneron will reduce prices on current and upcoming medications for Medicaid patients, offer discounts on its cholesterol fighter Praluent, and commit billions to U.S. manufacturing and free gene therapy for a rare hearing loss condition. Critics argue that these discounts mainly benefit government programs and may not significantly impact individual out-of-pocket expenses. The announcement comes as affordability remains a top concern for voters, and Trump continues to pressure for more affordable medications.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/675ecd0c55289f5d